ABCL vs MESO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABCL Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AbCellera Biologics Inc. Common Shares (ABCL) driven by superior Valuation, Momentum & Technical, Options & Structure while MESO counters with relative strength in Growth & Margin. Fundamentally, ABCL trades at 27.6x Forward P/E with -1550.0% operating margin (-76.3% YoY revenue) versus MESO at N/M Forward P/E and -42.6% operating margin (+390.7% YoY). In options structure, ABCL sits in CONSOLIDATION (25th %ile IV; Dealer Gamma Walls on Pro) against MESO sits in UNCLASSIFIED (37th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ABCL | MESO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.8B | $1.7B | Larger Scale | ABCL |
| Trailing P/E Ratio Valuation | 27.6x | N/M | Lower Multiple | ABCL |
| Forward P/E Ratio Valuation | 27.6x | N/M | Lower Multiple | ABCL |
| Revenue Growth (YoY) Growth | -76.3% | +390.7% | Higher Growth | MESO |
| Operating Margin (TTM) Profitability | -1550.0% | -42.6% | Higher Margin | MESO |
| Net Profit Margin Profitability | -248.8% | -47.8% | Higher Margin | MESO |
| Return on Equity (ROE) Capital Efficiency | -17.3% | -9.9% | Higher ROE | MESO |
| 52-Week Range Position Momentum | 69% ($3โ$15) | 6% ($12โ$22) | Stronger Trend | ABCL |
| Beta / 30D Volatility Risk Regime | 2.31ฮฒ ยท 87% Vol | 1.18ฮฒ ยท 78% Vol | Lower Realized Risk | MESO |
| Unified Institutional Score Composite Signal | 63.3 / 100 (BUY) | 35.5 / 100 (SELL) | Higher Composite | ABCL |